Key Takeaways
- • Private equity firms are scaling back new deal activity and redirecting capital toward portfolio company management as macroeconomic uncertainty, US tariffs, and recession risks make asset pricing increasingly difficult; multiple PE executives cite a "pause" in dealmaking with firms in "triage mode" to protect existing investments.
- • Limited partners face a constrained capital allocation environment, with major GPs using "fear and intimidation" tactics—including conditional access to flagship funds—to force LP commitments to new sub-strategies and side funds, fundamentally shifting LP-GP power dynamics.
- • GP stakes deal value reached $3.5 billion across 24 deals in 2025, the highest figure in over a decade, with managers increasingly selling minority stakes to bolster their own fund commitments and better align economics with LPs in a competitive fundraising environment.
- • Allocators are reducing commitment sizes and pulling back on new commitments due to longer holding periods, model uncertainty, and an exit backlog that has left billions in aging, underwater funds without clear liquidity timelines.
- • Notable deal delays include 3i's £600 million Audley Travel auction pause, Apax's £4 billion PIB insurance broker sale, and a bidder's reduction on Reckitt's $4–5 billion homecare portfolio from $3–4 billion, signaling broader hesitation among PE buyers.
Summary
The private equity market has entered a pronounced slowdown phase in early 2026, marking a dramatic reversal from industry optimism following the new US administration's arrival. PE firms are systematically scaling back new acquisitions and redirecting focus toward managing existing portfolio companies amid mounting macroeconomic headwinds. According to senior buyout executives, heightened recession risks, US tariff uncertainty under Donald Trump, and volatile pricing conditions have forced firms into what industry participants describe as "triage mode." One US-based executive stated flatly: "There is a pause… it's hard to price things," while a UK firm leader noted that "private equity will go really risk-off for a while. At times like this we become more focused on what we already have." This represents a stark contrast to late 2025 expectations of renewed deal momentum.
The slowdown extends across major transactions. While some deals have closed—including Silver Lake's stake in chip designer Altera and KKR's acquisition of Karo Healthcare—other processes have stalled or faced significant headwinds. 3i paused its £600 million Audley Travel auction, Apax's £4 billion sale of insurance broker PIB experienced repeated delays, and a bidder on Reckitt's $4–5 billion homecare brand portfolio trimmed its offer to the $3–4 billion range. Market advisers report that many firms have effectively gone "pens down," awaiting pricing stability and clarity before resuming acquisition activity.
The capital constraint is bidirectional. While GPs manage existing assets and pause new deals, limited partners are simultaneously pulling back on new commitments due to longer holding periods, model uncertainty, and a persistent exit backlog that has saddled the industry with billions in aging, underwater funds. Concurrently, GPs are leveraging their positioning in this constrained environment through aggressive fundraising tactics. According to allocators interviewed by Institutional Investor, top-tier managers are using conditional access to flagship funds as a bargaining chip, forcing LPs into commitments for sub-strategies and side funds. One endowment investor noted managers can effectively state: "You don't have access to a flagship fund until you seed the strategy." This dynamic reflects an inversion of traditional LP-GP power, with asset owners facing limited alternatives despite capital constraints.
In response to capital scarcity and LP skepticism, GP stakes have emerged as a strategic tool. Total GP stakes deal value reached $3.5 billion across 24 deals in 2025—the highest total in over a decade, according to PitchBook. Managers are using GP stakes proceeds to increase their own fund commitments, signaling alignment with LPs and bolstering their fundraising credentials during a competitive period. While some LPs remain skeptical about the implications of selling pieces of the GP relationship, advocates argue that the current Darwinian shakeout is forcing managers to demonstrate genuine skin-in-the-game commitments rather than pursuing AUM growth at the expense of performance.
The slowdown extends across major transactions. While some deals have closed—including Silver Lake's stake in chip designer Altera and KKR's acquisition of Karo Healthcare—other processes have stalled or faced significant headwinds. 3i paused its £600 million Audley Travel auction, Apax's £4 billion sale of insurance broker PIB experienced repeated delays, and a bidder on Reckitt's $4–5 billion homecare brand portfolio trimmed its offer to the $3–4 billion range. Market advisers report that many firms have effectively gone "pens down," awaiting pricing stability and clarity before resuming acquisition activity.
The capital constraint is bidirectional. While GPs manage existing assets and pause new deals, limited partners are simultaneously pulling back on new commitments due to longer holding periods, model uncertainty, and a persistent exit backlog that has saddled the industry with billions in aging, underwater funds. Concurrently, GPs are leveraging their positioning in this constrained environment through aggressive fundraising tactics. According to allocators interviewed by Institutional Investor, top-tier managers are using conditional access to flagship funds as a bargaining chip, forcing LPs into commitments for sub-strategies and side funds. One endowment investor noted managers can effectively state: "You don't have access to a flagship fund until you seed the strategy." This dynamic reflects an inversion of traditional LP-GP power, with asset owners facing limited alternatives despite capital constraints.
In response to capital scarcity and LP skepticism, GP stakes have emerged as a strategic tool. Total GP stakes deal value reached $3.5 billion across 24 deals in 2025—the highest total in over a decade, according to PitchBook. Managers are using GP stakes proceeds to increase their own fund commitments, signaling alignment with LPs and bolstering their fundraising credentials during a competitive period. While some LPs remain skeptical about the implications of selling pieces of the GP relationship, advocates argue that the current Darwinian shakeout is forcing managers to demonstrate genuine skin-in-the-game commitments rather than pursuing AUM growth at the expense of performance.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.